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Summary 
A novel frameshift mutation KCNH2 [ p.Asp896ArgfsX79] leading to malignant 
ventricular arrhythmias is identified. The proband presented with acute GI 
bleed,treatment of which with IKr blockers,  led to TdP VT and unmasking of LQTS.The 
management of this patient in the setting of chronic liver disease is underlined.The 
significance of variants in de novo mutations is also emphasized. 
 
Abstract 
A novel frameshift mutation in the KCNH2 gene for Long QT Syndrome Type 2 (LQTS2) 
was  identified after Torsades de Pointes ventricular tachycardia (TdP VT) in a 49-year 
old patient managed with octreotide and nadolol for an acute variceal bleed.  Inspite of 
removal of offending medications and correction of underlying electrolyte abnormalities, 
the patient’s QT interval remained  prolonged at 521 ms, raising the suspicion of an 
underlying channelopathy. Genetic studies confirmed heterozygosity for a novel 
frameshift mutation for KCNH2 gene, D896Rfs X79. We explore the pathogenicity and 
clinical impact of this variant mutation. 
 
Introduction 
LQTS2 is an inherited channelopathy that results in prolongation of the QT interval that 
may manifest clinically as TdP VT and sudden cardiac death if untreated. 
Almost two-thirds of the mutations of the KCNH2 gene are missense mutations, wherein 
a single change in the nucleotide sequence results in a defective amino acid causing loss 
         
of function of   ionic channel, Kv11.1. The remaining one third of the mutations of the 
KCNH2 gene are either nonsense mutations or frameshift mutations. These mutations, by 
modifying protein synthesis, generate impaired alpha subunits of the Kv11.1 ionic 
channel. 
We report a patient who presented with an acute gastrointestinal bleed, in whom therapy 
provoked TdP VT from QT prolonging drugs. Diagnostic work-up unmasked a novel 
frameshift mutation in the KCNH2 gene causing LQTS2. This variant mutation, 
D896RfsX79, has not been reported previously in the genome databases 
 
Case Presentation 
A 49-year old male, recently diagnosed with liver cirrhosis, presented with a 1-week 
history of shortness of breath and fatigue secondary to a recurrent variceal bleed. His 
medications included nadolol, furosemide, spironolactone, lansoprazole, and 
levothyroxine. His medical history included a remote mitral valve repair. He denied 
history of presyncope or syncope. There was no history of sudden cardiac death in his 
family. 
His vital signs were stable. Cardiorespiratory exam was normal. There was no evidence 
of chronic liver disease. 
His hemoglobin was 72 g/L, with abnormal liver function tests, and he had an elevated 
serum creatinine of 124 µmol/L. His admission potassium was 4.6 mmol/L. His ECG 
showed a resting HR of 68 bpm and QTc of 520 ms (Figure 1A). 
         
He was started on octreotide infusion (50 mcg/hr) after 50 mcg IV bolus along with 
nadolol therapy. He received 1 unit of packed red blood cells. Gastroscopy revealed 
grade II varices with active bleeding, treated with banding. Post-procedure, he developed 
syncope and was unresponsive. He was pulseless.  Telemetry showed Torsades de 
Pointes VT
1
 (Supplementary Figure S1). He was resuscitated with one cycle of 
cardiopulmonary resuscitation, single defibrillation, and a 2g of IV magnesium sulfate. 
His serum magnesium level was 0.67 mmol/L His heart rate had dipped to 47 bpm prior 
to the arrest and it remained in the 50s post code (Figure 2A and 2B). Telemetry strips 
documented early PVCs as the initiating event of the TdP VT (Figure 1B).  
He was started on isoproterenol infusion while octreotide and nadolol were discontinued.  
Echocardiography showed normal left ventricular systolic function and left heart 
catheterization showed normal coronaries. However, his QTc remained prolonged at 521 
ms raising the suspicion of an underlying channelopathy (Figure 1). 
A routine ECG done 5 years prior  showed a corrected QT interval of 426 ms. 
Interestingly the patient had not been diagnosed with liver cirrhosis at the time . Genetic 
modulation in the setting of  liver cirrhosis was thought to be unmasking QT- 
prolongation and possible channelopathy. 
 
Genetics 
Genetic analysis was carried out after discussion with patient, his wife and daughter 
about possible implications in case of a positive result. The following 12 genes currently 
known to be associated with LQTS were screened: KCNQ1,KCNH2,SCN5A, 
         
ANK2,KCNE1,KCNE2,KCNJ2,CACNA1C, CAV3,SCN4B,AKAP9 AND SNTA1. The 
patient was found to be heterozygous for a frame shift mutation in the KCNH2 gene for 
LQTS2 syndrome with insertion of two cytosines in the genomic sequence 
(c.2684_2685insCC) leading to a premature stop codon at position 79 of the new reading 
frame(p.Asp896ArgfxX79) potentially explaining his prolonged QT interval. This  
mutation causes a shift in reading frame starting at codon Aspartic acid 896 and  
changing it to an Arginine. As a class 1 mutation, it is expected to result in either an 
abnormal, truncated protein product or loss of protein from this allele through nonsense-
mediated RNA decay. At the molecular level the pore domain of the alpha subunit of the 
Ikr channel is affected, specifically transmembrane segments S5-S6 which contribute to 
the pore domain. 
The full transcript of the mutation is: c.2684_2685ins 
CC:p.Asp896ArgfsX79(D896RfsX79) in exon 11of the KCNH2 gene (NM_000238.2) 
(Supplementary figure S2). The normal sequence with the bases that are inserted in 
braces is: GCAC{CC}GCAC. The mutation is not reported in major variant databases. 
The patient’s only daughter declined screening and family screening could also not be 
performed as the patient was a first generation immigrant from India. 
 
Management 
He was offered an implantable cardioverter-defibrillator (ICD) for secondary prevention 
but he declined this therapy. However, he agreed to proceed with a permanent pacemaker 
implantation to prevent further episodes of bradycardia.  
         
 
Discussion 
This case highlights the unique challenges of managing acute GI bleed with beta-blockers 
and octreotide in the setting of undiagnosed Long QT Syndrome.  Both  pharmacologic 
agents likely caused his bradycardia, which is a known trigger for TdP VT under the 
setting of prolonged QT interval. In fact the patient suffered a perfect storm scenario with 
cirrhosis, a known QT prolonging condition, electrolyte abnormalities and acute illness. 
QT prolonging agents should be discontinued. It is optimal to keep potassium levels 
between 4.5-5 mmol/L.
3
 Beta-blockers are recommended in Long QT Syndrome with 
prolonged QT or those who had cardiac events.
4
. Our patient was on nadolol, though 
intended for  treatment of portal hypertension, had failed to prevent syncope, Torsades de 
Pointes, and pulseless VT during acute illness characterised by bradycardia and 
electrolyte abnormalities. This is not an uncommon phenomenon as one previous study 
had described that LQTS2 carriers despite being on beta-blocker therapy had higher rates 
of cardiac events compared to LQTS1 (23% vs 10% over 5 year period)
5
.  
In high risk patients in whom beta-blockade is ineffective or not tolerated, ICD therapy 
and/or left cardiac sympathetic denervation (LCSD) is indicated as per guidelines. There 
is a marked reduction in the incidence of arrhythmic SCD after LCSD; however in high 
risk patients with LQTS, recurrent lethal electric events have been reported in up to 50% 
of them
1
. LCSD is not an alternative to ICD but rather complementary to it. 
Around 20 years ago, it was found that one of the long QT causing genes was mapped to 
chromosome 7
6
. Later, it was determined that the KCNH2 (or HERG) gene codes for a 
         
potassium channel that facilitates the rapid component of the delayed outward-rectifying 
potassium current responsible for generating a QT interval
7
. Numerous mutations in this 
gene have since been reported and are thought to be responsible for prolonged QT which 
causes LQTS2. The mutation found in our case (c.2684_2685insCC) generates a 
premature termination codon at position 79 of the new reading frame 
(p.Asp896ArgfxX79) and is expected to result in a defective channel which clinically 
prolongs QT interval. Resulting haploinsufficiency would cause a milder phenotype, as 
only about 50% of the Kv11.1 channels would lose their function while the remaining 
function normally. This may explain the fact that our proband was asymptomatic prior to 
presentation. Other frameshift mutations in the KCNH2 gene have been reported in the 
HGMD(8). More recently Yoo et al. have reported a novel KCNH2 frameshift mutation 
(c.46delG) in a family with congenital LQTS2.(1) There was a high incidence of sudden 
cardiac death in this family and repeated syncopal spells in the proband, thus 
phenotypically very different from the proband reported in our case. 
It is important to underline the fact that not all truncating variants have been labeled as 
pathogenic. Clinvar reports 59 nonsense variants for KCNH2 out of which 51 are 
pathogenic, 4 are likely benign, 6 are likely pathogenic and 1 is uncertain status. 
Frameshift variants, as identified in our patient, also often end up in a downstream 
truncation. Clinvar identifies 187 of these; 148 being pathogenic, 8 uncertain status, 1 
likely benign and 5 conflicting interpretations. 
Experimental evidence for truncating variants have been reported by De Zio et al in an 
Italian family in which the proband suffered reccurent episodes of ventricular fibrillation 
arrest despite a QTc interval less than 500 ms, as well as C-terminally located mutation of 
         
the KCNH2 gene; both of which are predictive of a more benign course. However Moss 
et al have demonstrated in their study that patients with mutations exerting dominant- 
negative functional effect were more susceptible to arrhythmic events independent of 
clinical risk factors namely QTc duration, beta-blockade and gender. 
Thus in our patient the dominant-negative effect of the variant on the Ikr channel subunits 
over the wild -type  KCNH2 channel subunits may explain the pathogenicity of the 
mutation in spite of previously documented normal QTc of 426 ms and a previously 
benign cardiac history. 
The prevalence of LQTS has been a controversial topic and it is noteworthy that 
Schwartz et al had suggested  in 1975 that “LQTS is more unrecognized than rare.” In 
fact prevalence of silent mutations are high in LQT1 patients( 36%), moderate in LQT2 
patients(17%) and lower in LQT3 patients(10%). Thus undiagnosed LQTS may be a 
challenging  public health hazard that needs further probing  to identify new LQTS2 
patients before they suffer life-threatening electric events. 
 
Novel Learning Points 
1. A novel frameshift mutation( cDNA: c.2684_2685insCC; Variant:p.Asp896ArgfsX79) 
in the KCNH2 gene, consistent with a genetic form of LQTS2 is identified. 
2. Genetic Variants may modulate arrhythmic risk and may confer higher risk of life-
threatening electric events beyond traditional risk factors and inspite of normal QTc 
intervals. 
         
3. Cirrhosis of the liver has been associated with prolonged QT interval and this effect 
can be exacerbated by the use of Ikr blockers and other medications. LQTS may be 
unmasked in the process. 




Our case report describes a patient presenting with QT-prolongation and Torsades de 
Pointes ventricular tachycardia following a variceal bleed, in whom a heterozygous 
frameshift mutation resulting in a premature stop codon was identified in the KCNH2 
gene.  The use of Ikr blockers uncovered the  LQTS2 phenotype and enhanced the risk of 
TdP VT in this patient. 
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Figure 1. Electrocardiogram of a patient with congenital Long QT syndrome Type 2. (A) 
Patient was receiving octreotide infusion and nadolol for variceal bleed. QTc is ~520 ms. 
(B) Taken 60 hrs after Torsade de Pointes and monomorphic Ventricular Tachycardia. 
Despite correcting hypomagnesemia and bradycardia through Isoproterenol infusion, 
there still persists a prolonged QTc (~520 ms) indicating a raised possibility of congenital 
Long QT Syndrome. Evidence of macrovolt T wave alternans in precordial leads. 
  
  
         
 
Figure 2. (A) Pre-code ECG showing HR of 47 bpm and a QTC of 579 ms. (B) Post-
code ECG showing HR of 57 bpm and QTc of 578 ms. 
         
Supplementary Figure S1. Telemetry recordings of Torsade de Pointes VT.. Initiating 
early PVCs are seen prior to onset of TdP.  





         
